See more : Vishwaraj Sugar Industries Limited (VISHWARAJ.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Athira Pharma, Inc. (ATHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athira Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Central Pattana Public Company Limited (CPN.BK) Income Statement Analysis – Financial Results
- ESAF Small Finance Bank (ESAFSFB.NS) Income Statement Analysis – Financial Results
- Huron Valley Bancorp, Inc. (HVLM) Income Statement Analysis – Financial Results
- Avanti Acquisition Corp. (AVAN) Income Statement Analysis – Financial Results
- Softline Holding PLC (SFTL.IL) Income Statement Analysis – Financial Results
Athira Pharma, Inc. (ATHA)
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 969.00K | 1.05M | 479.00K | 2.00M | 0.00 | 0.00 |
| Gross Profit | -969.00K | -1.05M | -479.00K | -2.00M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.79M | 61.46M | 42.79M | 13.29M | 3.79M | 3.59M |
| General & Administrative | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Other Expenses | -1.63M | -5.16M | -8.84M | -1.32M | -754.00K | -164.00K |
| Operating Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Cost & Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Interest Income | 7.64M | 3.22M | 337.00K | 124.00K | 51.00K | 85.00K |
| Interest Expense | 0.00 | 24.32M | 3.00K | 367.00K | 346.00K | 9.00K |
| Depreciation & Amortization | 969.00K | 1.05M | 479.00K | 2.00M | 2.00K | 5.01M |
| EBITDA | -116.70M | -94.59M | -54.37M | -19.01M | -4.82M | -79.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -125.47M | -104.02M | -64.02M | -20.00M | -5.45M | -5.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.79M | 8.38M | 9.17M | 40.00K | 288.00K | -88.00K |
| Income Before Tax | -117.67M | -95.64M | -54.85M | -19.96M | -5.16M | -5.10M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.38M | -479.00K | -1.32M | -459.00K | -76.00K |
| Net Income | -117.67M | -87.26M | -54.37M | -18.63M | -4.70M | -5.10M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.10 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| EPS Diluted | -3.09 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| Weighted Avg Shares Out | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
| Weighted Avg Shares Out (Dil) | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease
ATHA Energy identifies new mineralized trends at Angilak uranium project
ATHA Energy advances exploration at Gemini and Angilak uranium projects
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
ATHA Energy signs LOI for joint venture on Canadian uranium projects
ATHA Energy Announces Proposed Option Agreements with Terra Uranium for Spire, Horizon, and Pasfield Projects
Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?
Source: https://incomestatements.info
Category: Stock Reports